Abstract:Background: The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. These proteins possess a prion-like property, enabling their transmission from cell to cell leading to propagation throughout the central and peripheral nervous systems. While the mechanisms underlying their intracellular spread are still being elucidated, targeting the extracellular space has emerged as a potential therapeutic approach. The glymphatic system, a brain-wide pathway responsible for clearing extracellular metabolic waste from the central nervous system, has gained attention as a promising target for removing these toxic proteins. Methods: In this study, we investigated the impact of long-term modulation of glymphatic function on tau aggregation and spread by chronically treating a mouse model of tau propagation with a pharmacological inhibitor of AQP4, TGN-020. Thy1-hTau.P301S mice were intracerebrally inoculated with tau into the hippocampus and overlying cortex, and subsequently treated with TGN-020 (3 doses/week, 50 mg/kg TGN-020, i.p.) for 10-weeks. During this time, animal memory was studied using cognitive behavioural tasks, and structural MR images were acquired of the brain in vivo prior to brain extraction for immunohistochemical characterisation. Results: Our findings demonstrate increased tau aggregation in the brain and transhemispheric propagation in the hippocampus following the inhibition of glymphatic clearance. Moreover, disruption of the glymphatic system aggravated recognition memory in tau inoculated mice and exacerbated regional changes in brain volume detected in the model. When initiation of drug treatment was delayed for several weeks post-inoculation, the alterations were attenuated. Conclusions: These results indicate that by modulating AQP4 function and, consequently, glymphatic clearance, it is possible to modify the propagation and pathological impact of tau in the brain, particularly during the initial stages of the disease. These findings highlight the critical role of the glymphatic system in preserving healthy brain homeostasis and offer valuable insights into the therapeutic implications of targeting this system for managing neurodegenerative diseases characterized by protein aggregation and spread.

Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

Glymphatic inhibition exacerbates tau propagation in an Alzheimer's disease model

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.

Glymphatic system, AQP4, and their implications in Alzheimer’s disease

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Influence of the Glymphatic System on α-Synuclein Propagation: Role of Aquaporin-4 and the Dystrophin-Associated Protein Complex

The Association of Enlarged Perivascular Space with Microglia-Related Inflammation and Alzheimer's Pathology in Cognitively Normal Elderly

Involvement of the glymphatic/meningeal lymphatic system in Alzheimer's disease: insights into proteostasis and future directions

Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis

Continuous Theta-Burst Stimulation Promotes Paravascular CSF-Interstitial Fluid Exchange through Regulation of Aquaporin-4 Polarization in APP/PS1 Mice

Matrix Metalloproteinase-9 Inhibition Prevents Aquaporin-4 Depolarization-Mediated Glymphatic Dysfunction in Parkinson’s Disease

GABA Promotes Interstitial Fluid Clearance in an AQP4-dependent Manner by Activating the GABAAR

Physiological Clearance of Tau in the Periphery and Its Therapeutic Potential for Tauopathies.

GABA promotes interstitial fluid clearance in an AQP4-dependent manner by activating the GABAA R

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Amelioration of Tau and ApoE4-linked Glial Lipid Accumulation and Neurodegeneration with an LXR Agonist.

Role of the Glymphatic System in Alzheimer's Disease and Treatment Approaches: A Narrative Review

The glymphatic system clears amyloid beta and tau from brain to plasma in humans

Multisensory gamma stimulation promotes glymphatic clearance of amyloid

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance